REDX PHARMA PLC
("Redx" or "the Company")

Exercise of Options and Total Voting Rights

Alderley Park, 8 July 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the exercise of share options by employees of the Company over 894,992 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 15.5 pence per share.

Application has been made to the London Stock Exchange for the 894,992 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am on 9 July 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 274,782,205 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

For further information, please contact:

Redx Pharma Plc
Peter Presland, Interim Chairman
Lisa Anson, Chief Executive
Peter Collum, Chief Financial Officer

T: +44 1625 469 918

SPARK Advisory Partners (Nominated Adviser)
Matt Davis/Adam Dawes

T: +44 203 368 3550

WG Partners LLP (Joint Broker)
Claes Spång/ David Wilson

T: +44 20 3705 9330

Panmure Gordon (UK) Limited (Joint Broker)
Rupert Dearden/Freddy Crossley/Emma Earl

T: +44 20 7886 2500

FTI Consulting
Simon Conway/Ciara Martin

T: +44 20 3727 1000

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx’s lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and Redx intends to report the Phase 1 clinical study results at a scientific meeting, as well as initiate multiple Phase 2 studies in H2 2021. The Company’s selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.